Clinical Trials Browser

zimberelimab × Genitourinary × 90 days × Clear all

NCT03547973 2026-03-16

TROPHY U-01

Phase 2 Recruiting

827 enrolled 1 FDA

Metastatic Urothelial Cancer

NCT06133517 2026-03-16

PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer

Phase 2 Active not recruiting

Urothelial Bladder Carcinoma

NCT05335941 2026-03-04

A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma

Phase 2 Active not recruiting

Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT05536141 2026-02-27

ARC-20

Phase 1 Recruiting

Erythrocytosis, Familial, 4, Carcinoma, Renal Cell, Kidney Neoplasms

NCT05891171 2026-02-27

ARC-25

Phase 1 Active not recruiting

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT07397611 2026-02-09

Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

Phase 2 Not yet recruiting

Carcinoma, Renal Cell, Kidney Neoplasms